

WORLD INTELLECTUAL PROPERTY UNGANIZATION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12P 37/00, 37/02, 35/00, C12N 15/00

A1

(11) International Publication Number:

WO 98/04732

(43) International Publication Date:

5 February 1998 (05.02.98)

(21) International Application Number:

PCT/US97/12181

(22) International Filing Date:

15 July 1997 (15.07.97)

(30) Priority Data:

60/022,622

26 July 1996 (26.07.96)

US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(72) Inventors: USHER, John, J.; 486 Summerhaven Drive, East Syracuse, NY 13057 (US). ROMANCIK, Guna; 6103 Thunderhead Lane, Jamesville, NY 13078 (US).

(74) Agents: ALMAULA, Prabodh, I. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SYNTHESIS OF β -LACTAM ANTIBACTERIALS USING SOLUBLE SIDE CHAIN ESTERS AND ENZYME ACYLASE

(57) Abstract

Disclosed is a process for the synthesis of θ -lactam antibacterials using soluble side chain esters in the presence of enzyme acylase. Also disclosed are novel esters useful as reactants in said process.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakis
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AU	• • · · - ·	GB	United Kingdom	MC	Monaco	TD	Chad
AZ Ba	Azerbaijan Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
	•	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BB	Barbados	GN	Guinca	MK	The former Yugoslav	TM	Turkmenistan
BE	Belgium	GR	Greece		Republic of Macedonia	TR	Turkey
BF	Burkina Faso	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BG	Bulgaria	IE	freland	MN	Mongolia	UA	Ukraine
BJ	Benin	IL.	Israel	MR	Mauritania	UG	Uganda
BR	Brazil	IS	Iceland	MW	Malawi	US	United States of America
BY	Belarus	IT	Italy	MX	Mexico	UZ.	Uzbekistan
CA	Canada	JP	Japan	NE	Niger	VN	Viet Nam
CF	Central African Republic	KE		NL	Netherlands	YU	Yugoslavia
CG	Congo		Kenya	NO	Norway	zw	Zimbabwe
СН	Switzerland	KG	Kyrgyzstan .	NZ	New Zealand	_	
CI	Côte d'Ivoire	KP	Democratic People's	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	и	Liechtenstein		Sweden		
DK	Denmark	LK	Sri Lanka	SE			
EE	Estonia	LR	Liberia	SG	Singapore		

SYNTHESIS OF β-LACTAM ANTIBACTERIALS USING SOLUBLE SIDE CHAIN ESTERS AND ENZYME ACYLASE

This application claims priority from provisional U.S. Application Serial No. 60/022,622, filed July 26, 1996, incorporated herein by reference in its entirety.

BEST AVAILABLE COPY

20

25

Field of the Invention

The present invention is directed to a process for the production of antibacterial β -lactams, namely penicillins and cephalosporins, in the presence of the enzyme, acylase, and a soluble ester as the acyl source. The invention is also directed to novel esters useful as reactants in said process.

Description of Related Art

Japanese Patent Application Publication Nos. 47-25388, 47-29588, 48-26985, 48-35090, 48-99393, 49-14687, 49-36890, 49-48892, 49-75787, 49-134893 and 52-110896 teach processes for preparing penicillins or cephalosporins by reacting a methyl or ethyl ester of the acyl moiety to be introduced, with 6-aminopenicillanic acid or 7-aminocephalosporanic acid or derivatives thereof. The acyl source in these references is a lower alkyl ester and especially a methyl ester. Eiji Kondo, et al., U.S. Patent No. 4,340,672, issued July 20, 1982, discloses a process for preparing antibacterial β-lactams, that is penicillins and cephalosporins, by the action of an acylase on a penicillin or cephalosporin nucleus amine and an ester(1) of the following formula as the acyl source

$$\begin{array}{c} \mathsf{RCOO}(\mathsf{CH_2CHO})_{\mathbf{n}}\mathsf{Y} \\ \mathsf{X} \end{array} \tag{I}$$

wherein RCO is an acyl group of penicillin or cephalosporin side chains; X is a hydrogen atom, lower alkyl group or hydroxy lower alkyl group; Y is a hydrogen atom or a lower alkyl group; and n is an integer from 1 to 20. The foregoing process uses the (poly)ethyleneglycol ester as the acyl source which is freely miscible with water as compared to known acyl sources, such as methyl esters, which have low solubility.

30

WO 92/01061, assigned to Novo Nordisk and published January 23, 1992, relates to a process for the preparation of β -lactam derivatives by enzymatic acylation of the parent amino β -lactam with amides as acylating agents.

Summary of the Invention

10

5

The present invention provides a novel process for preparing antibacterial β -lactams, that is penicillins and cephalosporins, by the action of an acylase on a penicillin or cephalosporin nucleus amine and an ester having the formula (II) as the acyl source

15

wherein RCO is a penicillin or cephalosporin side chain acyl group; R' is H or CH₂X or CHXY; R' is H or CH₂Y or CHXY and X and Y each are independently hydrogen, hydroxy, lower alkyl or hydroxy-lower alkyl.

Detailed Description of the Invention

20

As used in the specification, unless otherwise indicated explicitly or by context, the acyl group represented by RCO is an acyl of natural or synthetic, penicillins or cephalosporins. The lower alkyl includes alkyl of 1 to 4 carbon atoms.

25

One aspect of the present invention provides a process for the production of β -lactam antibacterials by reacting an ester of the formula (II) with aminoazetidinone carboxylic acid of the formula (III) in the presence of acylase in an aqueous medium to produce the β -lactam antibacterial of the formula (IV)

30

wherein RCO is an acyl group, NH₂-Q is an amino source and acylase is an enzyme of bacterial or fungal origin or obtained by recombinant methods. The substituents R' and R" are as defined above. The acyl group RCO can be straight, branched, cyclic, or partially

20

5 cyclic lower alkanoyl or lower alkenoyl; monocyclic lower aralkanoyl, monocyclic aryloxylower alkanoyl, (O, N, or S)-heterocyclic-lower alkanoyl, (O, N, or S)-heterocyclic thio-lower alkanoyl, cyanoacetyl, cyanomethyl-thioacetyl, monocyclic arylglycyl, monocyclic cycloalkenylglycyl, monocyclicarylglycolyl, N-acyl-arlglycyl, monocyclicarylmalonyl or arylsulfoalkanoyl, all above optionally having lower alkyl, aminomethyl, halogen, hydroxy, lower alkanoyloxy or lower alkoxy as a substituent, and preferably containing 1 to 15 carbon atoms.

The preferred RCO groups are D-phenylglycyl and 4-hydroxy-D-phenylglycyl which are well known as side chains of antibiotics such as cephalexin and amoxicillin.

The amino source NH₂-Q refers to the substituent on the 7-amino group or 6-amino group of known cephalosporin or penicillin antibiotics, Q having the fermula (VI)

$$CO_2H$$
 OR CO_2H

(VI)

wherein Z is hydrogen, halogen, lower alkyl of 1-3 carbon atoms, haloalkyl of 1-3 carbon atoms, C₂₋₄ alkenyl, a nucleophilic group or lower alkyl of 1-3 carbon atoms substituted by a nucleophilic group. The halogen atom is chlorine, bromine or iodine and the representative nucleophilic groups are disclosed in Japanese Patent Application Publication No. 49-81381.

The enzyme acylase can be of plant, animal, fungal or bacterial origin or obtained by recombinant methods. The bacterial or fungal acylases are especially important as far as production, efficiency, cost and stability are concerned.

Representative bacteria or fungi for the acylase source include strains of microorganisms belonging to, for example, genera <u>Acetobacter</u>, <u>Achromobacter</u>, <u>Aeromonas</u>, <u>Alkaligenes</u>, <u>Arthrobacter</u>, <u>Brevibacterium</u>, <u>Beneckea</u>, <u>Bacillus</u>, <u>Corynebacterium</u>, <u>Escherichia</u>, <u>Flavobacterium</u>, <u>Gluconobacter</u>, <u>Kluyvera</u>, <u>Microbacterium</u>, <u>Micrococcus</u>, <u>Nocardia</u>, <u>Proteus</u>, <u>Pseudomonas</u>, <u>Rhodopseudomonas</u>, <u>Spirillum</u>, <u>Staphylococcus</u>, <u>Xanthomonas</u>, <u>Aphanocladium</u> or <u>Cephalosporium</u>, or natural or artificial mutants or variants

10

15

20

25

30

of them capable of producing acylase for the reaction of this invention. Such strains include those described in, for example, *Advances in Applied Microbiology*, Volume 20, page 217 (1976), or natural or artificial mutants of them available for the reaction of this invention. An especially useful enzyme is penicillin G amidase which can be obtained from <u>Escherichia coli</u> by methods which are well known in the art. It can also be obtained by use of recombinant <u>E. Coli</u> containing the penicillin G amidase gene with a tac promoter by methods which are well known in the art. This method is preferred since it makes available large quantities of the enzyme suitable for the manufacturing process.

The aminoazetidinone carboxylic acid of formula (III) can be used as water soluble alkali metal salts, such as sodium, lithium and potassium, or as an ester, such as methanesulfonylethyl ester or acetonyl ester. The aminoazetidinones of formula (III) and its salts or esters are known compounds and can be prepared by known methods.

The esters of formula (II) can be prepared by known methods, that is, by reaction of an acid RCOOH with a diol or triol or polyol of the formula (V)

wherein RCO, R' and R" are as defined above. The esterificiation reaction can be by dehydration under acid catalyzed conditions or by means of acid halide or by ester exchange reactions. The RCOOH and the diol, triol or polyol are known compounds or can be obtained by methods which are well known in the art.

Another aspect of the invention provides the ester R-COO-CH₂-CH₂-OH wherein R is D-Phenylglycyl or 4-hydroxy-D-phenylglycl. These esters are novel and important reactants in the process of the invention because they provide yields of over 90% of the final products. These esters are prepared by known methods.

A preferred embodiment of the present invention is a process for preparing antibacterial β-lactams, that is, cefprozil, cefadroxil and amoxicillin by the action of penicillin G amidase on penicillin or cephalosporin amines of the following formula (VII)

10

15

20

25

30

$$H_2N$$
 S Z $COOH$ $G-APA$

(VII)

wherein Z is methyl (in 7-ADCA) or I-propenyl (in 7-PACA, the cefprozil nucleus) group and an ester of the formula (VIII)

wherein R is 4-hydroxy-D-phenylglycyl. The penicillin or cephalosporin amines of the formula (VII) are known compounds and can be obtained by methods well known in the art. The ester of formula (VIII) can be obtained by reacting RCOOH wherein R is defined as above with ethylene glycol. The compound RCOOH and ethylene glycol are commercially available.

The process of the invention is carried out by preparing a solution containing ester, cephalosporin or penicillin amine and the enzyme without a buffer at room temperature. This solution is prepared by dissolving the ester in water and adding ammonium hydroxide until a pH of 7.5 is reached. Then the penicillin or cephalosporin amine is added to the ester solution and the pH again adjusted to 7.5 with ammonium hydroxide. The mixture is then cooled to 5-15°C and the solid enzyme is added to it. During this time, the pH falls about 0.6 units and is not maintained at 7.5. The reaction mixture is then analyzed by high pressure liquid chromatography, for example on a C18 reversed phase column, 5 cm X 4.6 mm, 5µm spherosorb ODS2. The final product is obtained in a yield of 90-99%.

The process of this invention gives the final antibacterial β -lactam in the usual yield of over 90% and sometimes over 95% and occasionally over 99%. The yield obtained by simple alkyl esters, such as methyl are usually in the range of 70 to 90%. Because of the high yield of the final antibiotic obtained by the present process, the process is very useful for the manufacture of penicillin or cephalosporin antibiotics.

A typical reaction mixture contains 5-35% of the acyl source (VIII) (preferably 8-12%) and 2-20% of the amine source (VII) (preferably 2-5%). The enzyme can be present in a soluble or insoluble form, but preferably the enzyme is present in the form of an insoluble immobilized preparation. This preparation has advantages, such as improved stability of the

1 (

5 enzyme and also relative ease of removal of immobilized enzyme from reaction mixtures as a first step in the isolation of the antibiotic.

The invention is illustrated but in no way limited by the following Examples:

10

15

20

Example 1

Synthesis of cefprozil from (VII) using immobilized recombinant penicillin G amidase as the enzyme and hydroxyethyl ester of 4-hydroxy-D-phenylglycine prepared by acid catalyzed reaction as the acyl source

A mixture of 4-hydroxy-D-phenylglycine (10 g), ethylene glycol (15 ml) and concentrated sulphuric acid (5 ml) was stirred for 18 hours at 55°C under anhydrous conditions. The solution was cooled, and then ice (10 g) was added to it, and the pH was adjusted to 1.0 with 10 N-NH₄ OH (4.5 ml) giving 40 ml of solution of hydroxyethyl ester.

The enzyme mixture of 20 ml containing 10% ester, 4% (VII), and 8% enzyme (equivalent to 32 IU/ml of enzyme) was made up without buffer as follows:

The above prepared ester solution (6.9 ml) was mixed with water (2 ml) and adjusted to pH 7.5 with 10 N-NH₄OH. Then the compound (VII) (0.8 g) was added to it and the pH adjusted to 7.5 with 1 N-NH₄OH and the volume to 18.4 ml. Then the mixture was cooled to 5-15°C and solid enzyme (1.6 g; 640 IU) was added to it. The pH was not maintained at 7.5 and fell about 0.6 units during the reaction. The reaction mixture was analyzed by HPLC on a C18 Reverse Phase column 5 cm X 4.6 mm, 5µm spherosorb ODS2. The mobile phase was 10% acetonitrile/0.3% H₃PO₄ @ 2 ml/minute with 215 nm detection. The isomers of cefprozil appeared at 2.9 minutes (cis) and at 5.1 minutes (trans). The final product was obtained with a maximum yield of 92-96%. The whole experiment was completed in 25-50 minutes.

30

25

10

15

20

25

Example 2

Synthesis of cefprozil from (VII) using immobilized recombinant penicillin G amidase as the enzyme and purified hydroxyethyl ester of 4-hydroxy-D-phenylglycine as the acyl source

The purified ester was prepared by the reaction of the Dane salt of 4-hydroxy-D-phenylglycine with bromoethanol and was obtained as a pure crystalline hydrochloride salt.

The reaction mixture of 20 ml containing 12.5% ester, 4% (VII), and 8% enzyme (equivalent to 24 IU/ml of enzyme) was prepared as follows:

The purified ester (2.5 g), prepared as above, was mixed with water (9 ml) and adjusted to pH 8.0 with concentrated NH₄OH to give a solution. The compound (VII) (0.8 g) was added to the solution and the pH of the solution adjusted to 6.76 with 2M-H₂SO₄ and the volume to 18.4 ml. This solution was cooled to 5°C and then solid enzyme (1.6 g; 480 IU) was added to it. The pH was not maintained and fell about 0.6 units during the reaction. The final product was obtained in a maximum yield of 99%. The area percent of unreacted (VII) fell to 0.7%. The experiment was completed in twenty-five minutes.

Example 3

Synthesis of cefadroxil from 7-ADCA using Boehringer penicillin G amidase as the enzyme and hydroxyethyl ester of 4-hydroxy-D-phenylglycine prepared by acid catalyzed reaction as the acyl source

The ester was prepared as in Example 1. The experiment was repeated as in Example 1 but at 15°C and using 1.6 g of the Boehringer enzyme. The reaction mixture was analyzed by HPLC on a Merck column, 250-4, LiChrosorb RP-18 (10 μm), with 10% acetonitrile/1% NH₄H₂PO₄ as mobile phase run at 1.3 ml/minute with 280nm detection. The product was obtained with a maximum yield of ~95%. The experiment was completed in 35 minutes.

35

30

Example 4

Synthesis of amoxicillin from 6-APA using Boehringer penicillin G amidase as the enzyme and hydroxyethyl ester of 4-hydroxy-D-phenylglycine prepared by acid catalyzed reaction as the acyl source

10

15

A mixture of volume 20 ml containing 12% ester, 3% 6-APA, and 8% enzyme was prepared as follows:

A solution of the ester (prepared as in Example 1, 8.3 ml) was mixed with water (2 ml) and adjusted to pH 7.5 with 10 N-NH₄OH. Then the compound 6-APA (0.6 g) was added to the solution and the pH adjusted to ~7.0 with 1N ammonium hydroxide to a volume to 18.4 ml. Then the solution was cooled to 20°C and Boehringer enzyme (1.6 g) was added to it. This solution was analyzed by HPLC on a C18 Reverse Phase column 5cm X 4.6 mm, 5 µm spherosorb ODS 2. The mobile phase was 2.5% acetonitrile/0.025M NaH₂PO₄ to pH 3.5 with H₃PO₄ run @ 1 ml/minute with 215 nm detection. The final product was obtained in a yield of 90-95% in 160 minutes.

15

20

25

30

Claims

1. A process for producing a penicillin or cephalosporin comprising reacting an amine of the formula NH₂-Q (III), with an ester of the formula (II)

in the presence of an acylase, wherein Q is

wherein Z is hydrogen, halogen, lower alkyl of 1-3 carbon atoms, haloalkyl of 1-3 carbon atoms, C₂₋₄ alkenyl, a nucleophilic group or lower alkyl of 1-3 carbon atoms substituted by a nucleophilic group, RCO is straight, branched, cyclic, or partially cyclic lower alkanoyl or lower alkenoyl, monocyclic lower aralkanoyl, monocyclic aryloxylower alkanoyl, (O, N, or S)-heterocyclic-lower alkanoyl, cyanoacetyl, cyanomethyl-thioacetyl, monocyclic arylglycyl, monocyclic cycloalkenylglycyl, monocyclicarylglycolyl, N-acyl-arylglycyl, monocyclicarylmalonyl or arylsulfoalkanoyl, all above optionally having lower alkyl, aminomethyl, halogen, hydroxy, lower alkanoyloxy or lower alkoxy as a substituent, and containing 1 to 15 carbon atoms. R' is hydrogen, CH₂X or CHXY, R' is hydrogen, CH₂Y or CHXY, wherein X and Y each are independently hydrogen, hydroxy, lower alkyl or hydroxy-loweralkyl, to produce a penicillin or cephalosporin of the formula (IV)

RCONH-Q (IV), wherein RCO and Q are as defined above.

- 2. A process of claim 1, wherein NH₂-Q is a water soluble alkali metal salt or an ester.
- 3. A process of claim 1, wherein the acylase is immobilized recombinant penicillin G amidase.
- 4. A process for producing antibiotic cefprozil, cefadroxil or amoxicillin, comprising reacting

- 10 -

5

wherein Z is methyl or 1-propenyl group with an ester of the formula

wherein R is 4-hydroxy-D-phenylglycyl in the presence of the enzyme, penicillin G amidase to produce cefprozil, cefadroxil or amoxicillin.

10

- 5. The process of claim 4, wherein the enzyme is immobilized recombinant penicillin G amidase.
- 6. A compound of the formula R-COO-CH₂-CH₂-OH wherein R is D-phenylglycyl or 4-hydroxy-D-phenylglycyl.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/12181

•
•
•
•
_
• -
u
-
-
◂
•
•
~
-
e T
•
-
/b
_,
4
%
<u>и</u>

1	SSIFICATION OF SUBJECT MATTER		
IPC(6)	:C12P 37/00, 37/02, 35/00; C12N 15/00		
		national classification and IPC	
B. FIE	LDS SEARCHED		
Minimum	locumentation searched (classification system follower	d by classification symbols)	
U.S. :	435/43, 46, 47, 244, 230, 172.3		
	tion searched other than minimum documentation to the NOMENCLATURE	e extent that such documents are included	in the fields searched
	data base consulted during the international scarch (n. e Extra Sheet.	0, 37/02, 35/00: CL2N 15/00 47, 244, 230, 172.3 30 other than murimum documentation to the extent that such documents are included in the fields searched LATURE audited during the international search (name of data base and, where practicable, search terms used) 51. CONSIDERED TO BE RELEVANT 10 of document, with indication, where appropriate, of the relevant passages 11. CONSIDERED TO BE RELEVANT 12. 13. Synthesis of antibiotics 13. Synthesis of antibiotics 14. Synthesis of antibiotics 15. Singlycin) catalyzed by penicillin G acylase: Evaluation and alition of different synthetic approaches Enzyme and Microbial logy. 01 July 1996. Vol. 19, pages 9-14, especially page 15. O240 (I.B.S.A. INSTITUT BIOCHIMIQUE S.A.) 30 16. 17. Singlycin Catalyzed by penicillin G acylase: Evaluation and alition of different synthetic approaches Enzyme and Microbial logy. 01 July 1996. Vol. 19, pages 9-14, especially page 16. O240 (I.B.S.A. INSTITUT BIOCHIMIQUE S.A.) 30 17. Singlycin Catalyzed by the singly singlycin contains and singlycin contains the singly singlycin contains and singly singlycin contains and singly singlycin contains and singlycin contains a singly singlycin contains and singly singly singlycin contains and singly singly singly sing	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
Y	(cephaloglycin) catalyzed by penicillicoptimization of different synthetic appropriate the control of the contr	n G acylase: Evaluation and oaches Enzyme and Microbial	1-6
Y	CH 640240 (I.B.S.A. INSTITUT December 1983, Example 9.	BIOCHIMIQUE S.A.) 30	1-6
Y	WO 93/23164 A1 (NOVO NORDISK Example 2.	X A/S) 25 November 1993),	1-6
Y	WO 92/01061 A1 (NOVO NORDISK 6-8 and Examples.	A/S) 23 January 1992, pages	1-6
X Furth	er documents are listed in the continuation of Box C	. See patent family annex.	
• Sp	sous ostegories of cited documents.		
	nument defining the general state of the art which is not considered be of perticular relevance		
·L· do	tier document published on or after the international filling data cument which may throw doubts on priority claim(s) or which is	considered novel or cannot be consider	
	ed to establish the publication date of another citation or other scient reason (as specified)	•	
	cument referring to an oral disclosure, use, exhibition or other ens	combined with one or more other such	documents, such combination
	rument published prior to the international filing date but later than priority date claimed	'A' document member of the same patent	family
Date of the	actual completion of the international search	Date of mailing of the international sea	rch report
29 SEPTE	MBER 1997	0 4 DEC 1997	
Name and n	nailing address of the ISA/US	Authorized officer Tul +	2
Box PCT	ner of Patents and Trademarks a. D.C. 20231	IRENE MARX	-1
_	o. (703) 305-3230	Telephone No. (703) 308-0196	

INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/12181

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
ď	WO 93/12250 A1 (NOVO NORDISK A/S) 24 June 1993, Examples.	1-6
Y	WO 96/02663 A1 (GISTBROCADES B.V.) 01 February 1996, pages 7-9 and Examples.	1-6
		,
	BEST AVAILABLE COPY	
	- AVAILABLE COPY	
	,	
·	^ .·	

INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/12181

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used);

APS, CAS ONLINE, DIALOG, BIOSIS

Search terms: penicillin?, cephalosporin?, acylase?, amine?, ester?, immobiliz?, immobilis?, recombinant, penicillin G amidase, cefprozil, cefadroxil, amoxicillin Structure search

BEST AVAILABLE COPY